These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28576432)

  • 1. Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies.
    Sykam A; Gutlapalli VR; Tenali SP; Meena AK; Chandran P; Suneetha S; Suneetha LM
    J Clin Neurosci; 2017 Aug; 42():204-208. PubMed ID: 28576432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of tumor necrosis factor-alpha and interferon gamma gene polymorphisms and their plasma levels in leprosy, HIV and other peripheral neuropathies.
    Sykam A; Gutlapalli VR; Tenali SP; Meena AK; Chandran P; Pratap DVS; Suneetha S; Suneetha LM
    Cytokine; 2015 Dec; 76(2):473-479. PubMed ID: 26431782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to myelin P0 and ceramide perpetuate neuropathy in long standing treated leprosy patients.
    Raju R; Devi SK; Mehervani C; Kumar AS; Meena AK; Reddy PP; Pranay P; Jain S; Archelos-Gracia JJ; Suneetha S; Suneetha LM
    Neurochem Res; 2011 May; 36(5):766-73. PubMed ID: 21234675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ceramide antibodies in leprosy: marker for nerve damage?
    Singh K; Singh B; Ray P
    J Infect Dev Ctries; 2010 Jun; 4(6):378-81. PubMed ID: 20601789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in acetylcholinesterase and butyrylcholinesterase activities in chronic obstructive pulmonary disease: relationships with oxidative and inflammatory markers.
    Ben Anes A; Ben Nasr H; Garrouch A; Bennour S; Bchir S; Hachana M; Benzarti M; Tabka Z; Chahed K
    Mol Cell Biochem; 2018 Aug; 445(1-2):1-11. PubMed ID: 29234928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-heparan sulfate antibodies in neurological disease.
    Briani C; Ruggero S; Alaedini A; Nardelli E; Ferrari S; Wirguin I; Zara G; Battistin L; Latov N
    Muscle Nerve; 2002 Nov; 26(5):713-5. PubMed ID: 12402295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
    Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
    Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV peripheral neuropathy.
    Gabbai AA; Castelo A; Oliveira AS
    Handb Clin Neurol; 2013; 115():515-29. PubMed ID: 23931799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune peripheral neuropathies.
    Bourque PR; Chardon JW; Massie R
    Clin Chim Acta; 2015 Sep; 449():37-42. PubMed ID: 25748038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Butyrylcholinesterase activity in schizophrenic patients].
    Mabrouk H; Mechria H; Mechri A; Rahali H; Douki W; Gaha L; Fadhel Najjar M
    Ann Biol Clin (Paris); 2011; 69(6):647-52. PubMed ID: 22123563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of neuropathies associated with elevated IgM serum levels.
    Goldfarb AR; Sander HW; Brannagan TH; Magda P; Latov N
    J Neurol Sci; 2005 Feb; 228(2):155-60. PubMed ID: 15694197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Contribution of autoantibodies to the diagnosis of peripheral neuropathies].
    Antoine JC
    Rev Med Liege; 2004; 59 Suppl 1():133-40. PubMed ID: 15244169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy.
    Ge S; Xie J; Zheng L; Yang L; Zhu H; Cheng X; Shen F
    Diabetes Res Clin Pract; 2016 May; 115():68-75. PubMed ID: 27242125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls.
    Uetz-von Allmen E; Sturzenegger M; Rieben R; Rihs F; Frauenfelder A; Nydegger UE
    Eur Neurol; 1998; 39(2):103-10. PubMed ID: 9520071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?
    Josviak ND; Batistela MS; Souza RKM; Wegner NR; Bono GF; Sulzbach CD; Simão-Silva DP; Piovezan MR; Souza RLR; Furtado-Alle L
    Int J Neurosci; 2017 Dec; 127(12):1082-1086. PubMed ID: 28504037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of platelets morphological changes and serum butyrylcholinesterase activity in children with diabetic ketoacidosis: a case control study.
    Mousa SO; Sayed SZ; Moussa MM; Hassan AH
    BMC Endocr Disord; 2017 Apr; 17(1):23. PubMed ID: 28376867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Butyrylcholinesterase as a biochemical marker.
    Pohanka M
    Bratisl Lek Listy; 2013; 114(12):726-34. PubMed ID: 24329513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced serum butyrylcholinesterase activity indicates severe systemic inflammation in critically ill patients.
    Zivkovic AR; Schmidt K; Sigl A; Decker SO; Brenner T; Hofer S
    Mediators Inflamm; 2015; 2015():274607. PubMed ID: 25762852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Serum Anti-Ceramide Antibodies and Interleukin 4 on Nerve Damage and Physical Impairments Among Leprotic Patients: A Case-Controlled Study.
    Zaky M; Obaid Z; Khedr M; El-Sokkary H; Elsaie M
    J Drugs Dermatol; 2022 Mar; 21(3):284-291. PubMed ID: 35254767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.